{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:29:31Z","timestamp":1793640571459,"version":"4.5.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40257-026-01065-8","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:26:41Z","timestamp":1786447601000},"page":"1145-1160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Biologic Therapies on the Risk of Progression from Psoriasis to Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3881-0266","authenticated-orcid":false,"given":"Wenhui","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"1","key":"1065_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00630-5","volume":"11","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Blauvelt A, Callis Duffin K, et al. Psoriasis. Nat Rev Dis Primers. 2025;11(1):45. https:\/\/doi.org\/10.1038\/s41572-025-00630-5.","journal-title":"Nat Rev Dis Primers"},{"key":"1065_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Global Psoriasis Atlas, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https:\/\/doi.org\/10.1136\/bmj.m1590.","journal-title":"BMJ"},{"issue":"3","key":"1065_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153\u201366. https:\/\/doi.org\/10.1038\/s41584-019-0175-0.","journal-title":"Nat Rev Rheumatol"},{"key":"1065_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103202","volume":"145","author":"Z Kang","year":"2024","unstructured":"Kang Z, Zhang X, Du Y, Dai SM. Global and regional epidemiology of psoriatic arthritis in patients with psoriasis: a comprehensive systematic analysis and modelling study. J Autoimmun. 2024;145:103202. https:\/\/doi.org\/10.1016\/j.jaut.2024.103202.","journal-title":"J Autoimmun"},{"issue":"9","key":"1065_CR5","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1093\/rheumatology\/keab357","volume":"60","author":"W Xie","year":"2021","unstructured":"Xie W, Huang H, Ji L, Zhang Z. Maternal and neonatal outcomes in pregnant women with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(9):4018\u201328. https:\/\/doi.org\/10.1093\/rheumatology\/keab357.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1065_CR6","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard-2023-224148","volume":"82","author":"A Zabotti","year":"2023","unstructured":"Zabotti A, De Marco G, Gossec L, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162\u201370. https:\/\/doi.org\/10.1136\/ard-2023-224148.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1065_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jaad.2020.08.060","volume":"84","author":"W Xie","year":"2021","unstructured":"Xie W, Huang H, Deng X, Gao D, Zhang Z. Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2021;84(3):701\u201311. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.060.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1065_CR8","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(24)00268-6","volume":"7","author":"F Ciccia","year":"2025","unstructured":"Ciccia F, Gandolfo S, Caporali R, Scher JU. Understanding the spectrum from preclinical psoriatic arthritis to early diagnosis of the disease. Lancet Rheumatol. 2025;7(3):e208\u201311. https:\/\/doi.org\/10.1016\/S2665-9913(24)00268-6.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"1065_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40257-025-00968-2","volume":"26","author":"JF Merola","year":"2025","unstructured":"Merola JF, Warren RB, Tha\u00e7i D, et al. Bimekizumab complete clearance of both skin and nail psoriasis: comparative efficacy in phase III\/IIIb studies. Am J Clin Dermatol. 2025;26(6):967\u201379. https:\/\/doi.org\/10.1007\/s40257-025-00968-2.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1065_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40257-025-00949-5","volume":"26","author":"D Ranzinger","year":"2025","unstructured":"Ranzinger D, Eyerich K. Disease modification in psoriasis: future prospects for long-term remission. Am J Clin Dermatol. 2025;26(4):477\u201386. https:\/\/doi.org\/10.1007\/s40257-025-00949-5.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1065_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2023","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2023;83(6):706\u201319. https:\/\/doi.org\/10.1136\/ard-2024-225531.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1065_CR12","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2665-9913(25)00348-0","volume":"8","author":"D McGagh","year":"2026","unstructured":"McGagh D, Elliott A, Grohmann T, et al. The path to interception in psoriatic disease: from conceptual clarity to clinical translation. Lancet Rheumatol. 2026;8(3):e217\u201327. https:\/\/doi.org\/10.1016\/S2665-9913(25)00348-0.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"1065_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/art.43396","volume":"78","author":"H Gra\u00dfhoff","year":"2026","unstructured":"Gra\u00dfhoff H, Comd\u00fchr S, Nording H, et al. Transition from psoriasis to psoriatic arthritis is characterized by distinct alterations in peripheral blood Tc17, Th17, and CD4+ effector memory cells. Arthritis Rheumatol. 2026;78(2):332\u201343. https:\/\/doi.org\/10.1002\/art.43396.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1065_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004176","volume":"10","author":"T Grohmann","year":"2024","unstructured":"Grohmann T, Vivekanantham A, Coates LC, Pennington S, FitzGerald O. Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature. RMD Open. 2024;10(4):e004176. https:\/\/doi.org\/10.1136\/rmdopen-2024-004176.","journal-title":"RMD Open"},{"issue":"1","key":"1065_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaad.2025.09.003","volume":"94","author":"Z Liu","year":"2026","unstructured":"Liu Z, Chen J, Zhou K, et al. Effectiveness of biologics on synovitis and enthesitis using musculoskeletal ultrasound assessment in subclinical psoriatic arthritis: a 12-week observational real-world study. J Am Acad Dermatol. 2026;94(1):41\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2025.09.003.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"1065_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3899\/jrheum.2023-0506","volume":"50","author":"ER Soriano","year":"2023","unstructured":"Soriano ER, Ogdie A. Can early aggressive treatment of psoriasis prevent psoriatic arthritis? A debate at the GRAPPA annual meeting. J Rheumatol. 2023;50(Suppl 2):8\u201310. https:\/\/doi.org\/10.3899\/jrheum.2023-0506.","journal-title":"J Rheumatol"},{"issue":"6","key":"1065_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40257-023-00801-8","volume":"24","author":"A Aronovich","year":"2023","unstructured":"Aronovich A, Novikov I, Pavlovsky L. Do biologic treatments for psoriasis lower the risk of psoriatic arthritis? A systematic review. Am J Clin Dermatol. 2023;24(6):865\u201373. https:\/\/doi.org\/10.1007\/s40257-023-00801-8.","journal-title":"Am J Clin Dermatol"},{"key":"1065_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241266727","volume":"16","author":"O Hen","year":"2024","unstructured":"Hen O, Harrison SR, De Marco G, Marzo-Ortega H. Early psoriatic arthritis: when is the right time to start advanced therapy? Ther Adv Musculoskelet Dis. 2024;16:1759720X241266727. https:\/\/doi.org\/10.1177\/1759720X241266727.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"1065_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","volume":"81","author":"E Meer","year":"2022","unstructured":"Meer E, Merola JF, Fitzsimmons R, et al. Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis. 2022;81(1):80\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220761.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1065_CR20","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/acr.25539","volume":"77","author":"L Eder","year":"2025","unstructured":"Eder L, Li X, Chandran V, Rosen CF, Cook RJ, Gladman DD. Association of higher levels of high-sensitivity C-reactive protein with future development of psoriatic arthritis in psoriasis: a prospective cohort study. Arthritis Care Res (Hoboken). 2025;77(11):1288\u201392. https:\/\/doi.org\/10.1002\/acr.25539.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"1065_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jaad.2021.09.019","volume":"86","author":"JF Merola","year":"2022","unstructured":"Merola JF, Tian H, Patil D, et al. Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health records database in the United States. J Am Acad Dermatol. 2022;86(4):748\u201357. https:\/\/doi.org\/10.1016\/j.jaad.2021.09.019.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1065_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"7650","key":"1065_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, GRADE Working Group, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"3","key":"1065_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ard.2025.10.007","volume":"85","author":"W Xie","year":"2026","unstructured":"Xie W, Chen T, Xiao S, Huang H, Zhang Z. Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence. Ann Rheum Dis. 2026;85(3):417\u201324. https:\/\/doi.org\/10.1016\/j.ard.2025.10.007.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1065_CR25","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1016\/S2665-9913(26)00041-X","volume":"8","author":"W Xie","year":"2026","unstructured":"Xie W, Chen T, Chen Y, Zhang Z, Xiao S. Associated lifestyle factors and comorbidities of difficult-to-treat rheumatoid arthritis: a systematic review and meta-analysis. Lancet Rheumatol. 2026;8(6):e425\u201337. https:\/\/doi.org\/10.1016\/S2665-9913(26)00041-X.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1065_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","volume":"81","author":"ML Acosta Felquer","year":"2022","unstructured":"Acosta Felquer ML, LoGiudice L, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220865.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1065_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2021-219961.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1065_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/art.41946","volume":"74","author":"YS Rosenthal","year":"2022","unstructured":"Rosenthal YS, Schwartz N, Sagy I, Pavlovsky L. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study. Arthritis Rheumatol. 2022;74(2):237\u201343. https:\/\/doi.org\/10.1002\/art.41946.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1065_CR29","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","volume":"5","author":"S Singla","year":"2023","unstructured":"Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200\u20137. https:\/\/doi.org\/10.1016\/S2665-9913(23)00034-6.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"1065_CR30","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.jaad.2024.06.106","volume":"91","author":"B Strober","year":"2024","unstructured":"Strober B, Soliman AM, Li C, Patel M, Unigwe I, Gisondi P. Risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics: a population-based analysis. J Am Acad Dermatol. 2024;91(6):1143\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2024.06.106.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1065_CR31","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40744-024-00680-3","volume":"11","author":"A Watad","year":"2024","unstructured":"Watad A, Zabotti A, Patt YS, et al. From psoriasis to psoriatic arthritis: decoding the impact of treatment modalities on the prevention of psoriatic arthritis. Rheumatol Ther. 2024;11(4):963\u201376. https:\/\/doi.org\/10.1007\/s40744-024-00680-3.","journal-title":"Rheumatol Ther"},{"issue":"suppl 3","key":"1065_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/bjd\/ljae360.060","volume":"191","author":"S Robinson","year":"2024","unstructured":"Robinson S, Teoh XY, Yahya ZA, et al. P30 Disease burden, treatment outcomes and new onset of cardiometabolic diseases and psoriatic arthritis with biologics and non-biologics in The Malaysian Psoriasis Registry patients: 10 years data. Br J Dermatol. 2024;191(suppl 3):30. https:\/\/doi.org\/10.1093\/bjd\/ljae360.060.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1065_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40259-024-00689-8","volume":"39","author":"Y Cho","year":"2025","unstructured":"Cho Y, Park S, Jung K, et al. Effect of biological therapy for psoriasis on the development of psoriatic arthritis: a population-based cohort study. BioDrugs. 2025;39(1):143\u201352. https:\/\/doi.org\/10.1007\/s40259-024-00689-8.","journal-title":"BioDrugs"},{"issue":"3","key":"1065_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ard.2025.01.006","volume":"84","author":"P Gisondi","year":"2025","unstructured":"Gisondi P, Bellinato F, Galeone C, et al. Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics. Ann Rheum Dis. 2025;84(3):435\u201341. https:\/\/doi.org\/10.1016\/j.ard.2025.01.006.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1065_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf489","volume":"65","author":"TL Lin","year":"2026","unstructured":"Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Psoriatic arthritis risk in psoriasis patients receiving anti-IL-23 vs anti-IL-17: comparison of drug classes and individual agents. Rheumatology (Oxford). 2026;65(1):keaf489. https:\/\/doi.org\/10.1093\/rheumatology\/keaf489.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1065_CR36","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/jdv.70167","volume":"40","author":"KL Miao","year":"2026","unstructured":"Miao KL, Huang MY, Guo L, Lung K, Armstrong AW. Effect of biologic use on the development of psoriatic arthritis: a population-based study. J Eur Acad Dermatol Venereol. 2026;40(5):900\u20137. https:\/\/doi.org\/10.1111\/jdv.70167.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1065_CR37","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1093\/rheumatology\/keaf364","volume":"64","author":"S Piaserico","year":"2025","unstructured":"Piaserico S, Megna M, Bardazzi F, Magnano M, Giovanardi G, Odorici G, et al. TNF-alpha inhibitors reduce the incidence of PsA in patients with psoriasis: a propensity score-matched cohort study. Rheumatology (Oxford). 2025;64(11):5803\u201310. https:\/\/doi.org\/10.1093\/rheumatology\/keaf364.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1065_CR38","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jaad.2024.07.1473","volume":"91","author":"SHL Tsai","year":"2024","unstructured":"Tsai SHL, Yang CY, Huo AP, Wei JC. Interleukin 2 versus interleukin 12\/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX global collaborative network. J Am Acad Dermatol. 2024;91(5):889\u201395. https:\/\/doi.org\/10.1016\/j.jaad.2024.07.1473.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1065_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40259-025-00705-5","volume":"39","author":"S Yu","year":"2025","unstructured":"Yu S, Huo AP, Wang YH, Wei JC. Interleukin-23 versus interleukin-17 inhibitors in preventing incidental psoriatic arthritis in patients with psoriasis: a real-world comparison from the TriNetX US collaborative network. BioDrugs. 2025;39(2):297\u2013306. https:\/\/doi.org\/10.1007\/s40259-025-00705-5.","journal-title":"BioDrugs"},{"issue":"4","key":"1065_CR40","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jaad.2025.12.093","volume":"94","author":"RK Islam","year":"2026","unstructured":"Islam RK, Lipner SR, Wu JJ. Interleukin-23 inhibitors are associated with reduced incidence of psoriatic arthritis: insights from TriNetX. J Am Acad Dermatol. 2026;94(4):1333\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2025.12.093.","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 9","key":"1065_CR41","first-page":"2857","volume":"77","author":"U Kiltz","year":"2025","unstructured":"Kiltz U, Sfikakis P, Bounas A, et al. Effective prevention of psoriatic arthritis with secukinumab: a 5-year observation from the SERENA study. Arthritis Rheumatol. 2025;77(suppl 9):2857\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1065_CR42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","volume":"21","author":"E Kampylafka","year":"2019","unstructured":"Kampylafka E, Simon D, d\u2019Oliveira I, et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):178. https:\/\/doi.org\/10.1186\/s13075-019-1957-0.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1065_CR43","doi-asserted-by":"publisher","first-page":"e063650","DOI":"10.1136\/bmjopen-2022-063650","volume":"12","author":"RH Haberman","year":"2022","unstructured":"Haberman RH, MacFarlane KA, Catron S, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022;12(12):e063650. https:\/\/doi.org\/10.1136\/bmjopen-2022-063650. (Erratum in: BMJ Open. 2023;13(4):e063650corr1. 10.1136\/bmjopen-2022-063650corr1).","journal-title":"BMJ Open"},{"issue":"4-5","key":"1065_CR44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"E Suzuki","year":"2014","unstructured":"Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13(4\u20135):496\u2013502. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.050.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"1065_CR45","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.38638","volume":"66","author":"H Benham","year":"2014","unstructured":"Benham H, Rehaume LM, Hasnain SZ, Velasco J, Baillet AC, Ruutu M, et al. Interleukin-23 mediates the intestinal response to microbial \u03b2-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol. 2014;66(7):1755\u201367. https:\/\/doi.org\/10.1002\/art.38638.","journal-title":"Arthritis Rheumatol"},{"key":"1065_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01550","volume":"9","author":"MN van Tok","year":"2018","unstructured":"van Tok MN, Na S, Lao CR, Alvi M, Pots D, van de Sande MGH, et al. The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling. Front Immunol. 2018;9:1550. https:\/\/doi.org\/10.3389\/fimmu.2018.01550.","journal-title":"Front Immunol"},{"issue":"77","key":"1065_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3254","volume":"7","author":"SK Whitley","year":"2022","unstructured":"Whitley SK, Li M, Kashem SW, et al. Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells. Sci Immunol. 2022;7(77):eabq3254. https:\/\/doi.org\/10.1126\/sciimmunol.abq3254.","journal-title":"Sci Immunol"},{"key":"1065_CR48","doi-asserted-by":"publisher","first-page":"1346757","DOI":"10.3389\/fmed.2024.1346757","volume":"11","author":"B Lob\u00e3o","year":"2024","unstructured":"Lob\u00e3o B, Louren\u00e7o D, Giga A, Mendes-Bastos P. From PsO to PsA: the role of TRM and Tregs in psoriatic disease, a systematic review of the literature. Front Med (Lausanne). 2024;11:1346757. https:\/\/doi.org\/10.3389\/fmed.2024.1346757.","journal-title":"Front Med (Lausanne)."},{"issue":"7","key":"1065_CR49","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","volume":"141","author":"H Mehta","year":"2021","unstructured":"Mehta H, Mashiko S, Angsana J, et al. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs secukinumab. J Invest Dermatol. 2021;141(7):1707-1718.e9. https:\/\/doi.org\/10.1016\/j.jid.2021.01.005.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1065_CR50","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1172\/JCI133159","volume":"130","author":"AC Billi","year":"2020","unstructured":"Billi AC, Ludwig JE, Fritz Y, et al. KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease. J Clin Investig. 2020;130(6):3151\u20137. https:\/\/doi.org\/10.1172\/JCI133159.","journal-title":"J Clin Investig"},{"issue":"3","key":"1065_CR51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2018.17","volume":"14","author":"K Oikonomopoulou","year":"2018","unstructured":"Oikonomopoulou K, Diamandis EP, Hollenberg MD, Chandran V. Proteinases and their receptors in inflammatory arthritis: an overview. Nat Rev Rheumatol. 2018;14(3):170\u201380. https:\/\/doi.org\/10.1038\/nrrheum.2018.17.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1065_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41590-025-02351-z","volume":"27","author":"MG Raimondo","year":"2026","unstructured":"Raimondo MG, Mohammadian H, Angeli MR, et al. Skin-derived myeloid precursors and joint-resident fibroblasts spread psoriatic disease from skin to joints. Nat Immunol. 2026;27(1):35\u201347. https:\/\/doi.org\/10.1038\/s41590-025-02351-z.","journal-title":"Nat Immunol"},{"issue":"8","key":"1065_CR53","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/pds.3447","volume":"22","author":"MM Asgari","year":"1996","unstructured":"Asgari MM, Wu JJ, Gelfand JM, et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiol Drug Saf. 1996;22(8):842\u20139. https:\/\/doi.org\/10.1002\/pds.3447.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1065_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098024","volume":"9","author":"S L\u00f6fvendahl","year":"2014","unstructured":"L\u00f6fvendahl S, Theander E, Svensson \u00c5, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden\u2014a population-based register study. PLoS\u00a0One. 2014;9(5):e98024. https:\/\/doi.org\/10.1371\/journal.pone.0098024.","journal-title":"PLoS\u00a0One"},{"key":"1065_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.847160","volume":"13","author":"W Xie","year":"2022","unstructured":"Xie W, Xiao S, Huang H, Zhang Z. Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis. Front Immunol. 2022;13:847160. https:\/\/doi.org\/10.3389\/fimmu.2022.847160.","journal-title":"Front Immunol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01065-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01065-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01065-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:02:38Z","timestamp":1793638958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01065-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01065-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest relevant to the content of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data supporting the findings of this study are available from the corresponding author upon reasonable request. No publicly archived datasets were analyzed or generated.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a systematic review and meta-analysis of previously published studies. No ethical approval was required as no human participants were directly involved.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this study did not involve human participants.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this manuscript contains no individual person\u2019s data or images.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No custom code was developed for this analysis. All statistical analyses were performed using R software (version 4.5.2) with the meta package, which are publicly available.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shiyu Xiao and Wenhui Xie had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Shiyu Xiao, Wenhui Xie. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Wenhui Xie. Critical review of the manuscript for important intellectual content: All authors. Statistical analysis: Wenhui Xie, Tong Chen, Shiyu Xiao. Administrative, technical, or material support: Yuan Chen. Supervision: Shiyu Xiao. All authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}